Kornimate/medical-research-clean huggingface dataset:
pediatric burn treatment using tilapia skin as a xenograft for superficial-partial thickness wounds

Conditions: Burns

Summary: this study aims to evaluate the efficacy of nile tilapia skin as a xenograft for the treatment of partial-thickness burn wounds in children.

this is an open-label, monocentric, randomized phase ii pilot study conducted in fortaleza, brazil. the study population consisted of 30 children between the ages of 2 and 12 years with superficial "partial-thickness" burns admitted less than 72 hours from the thermal injury. in the test group, the tilapia skin was applied. in the control group, a thin layer of silver sulfadiazine cream 1% was applied.

Eligibility criteria:
inclusion criteria: * children between the ages of 2 and 12 years admitted to our institution with superficial partial thickness burns less than 72 hours from the thermal injury exclusion criteria: * patients were excluded for a burn greater than 15% total body surface area (tbsa); * presence of a previous treatment for the current burn; * presence of a chemical or electrical burn; * presence of other significant diseases that could impact the volunteer's participation in the study; * presence of hypersensitivity to materials used in the study or to related compounds.

Keywords: burns wounds and injuries biocompatible materials nile tilapia oreochromis niloticus
impact of somasignal tests on the choice of glucose-lowering medications

Conditions: Type 2 Diabetes; Cardiovascular Diseases

Summary: the purpose of this study is to learn more about using a proteomic test called the somasignal cardiovascular (cv) risk test in type 2 diabetes (cvd-t2d) to improve medical care for patients.


Eligibility criteria:
inclusion criteria: provider * licensed provider actively practicing medicine at a uc health clinic that routinely provides medical treatment for patients with type 2 diabetes inclusion criteria: patient * patients receiving care at a uc health system * age 40 years or older * type 2 diabetes * eligible for (per drug label/guidelines) at least one of the following classes: sglt2i, pcsk9i, glp-1 ra * able to provide consent exclusion criteria: * use of sglt2i , glp1ra and pcsk9i within the 3 months prior to enrollment * systemic lupus erythematous (sle)\* * pregnancy (as determined by self report) * intolerance or contraindication for use of both glp1ra and sglt2i * history of, an active, or untreated malignancy, in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years prior to, or are receiving or planning to receive therapy for cancer, at screening * samples provided by patients with sle may fail to produce results or may produce inaccurate results because autoantibodies in the patient plasma may interact with the dna-based reagents used in the assay

Keywords: proteomics t2d type 2 diabetes mellitus cvd
cardiorespiratory training and ventilatory muscle strength

Conditions: Sarcopenia

Summary: the cardiorespiratory training can increase muscle strength ventilatory.

specifically for being an experiment parallel factorial intervention after met the eligibility criteria for the participants will be randomly allocated to three groups: control, respiratory training, cardiorespiratory training (indoor bike).

Eligibility criteria:
inclusion criteria: - have lower maximal inspiratory pressure (mip) and maximal expiratory pressure (mep) values normative reference proposed by the brazilian society of thoracic. exclusion criteria: * not be voluntary to the present study. * conditions that oblige participants are absent for more than two weeks of activities performed in the experiment.
a study of saquinavir used alone or in combination with other anti-hiv drugs in hiv-infected patients

Conditions: HIV Infections

Summary: to offer an investigational agent (saquinavir) to people with hiv/aids who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials. patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquinavir trials are eligible for this compassionate treatment program.

patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquinavir trials are eligible for this compassionate treatment program. patients may be registered with the program through their physicians, who will be responsible for supervising the administration of treatment; following guidelines for saquinavir dose interruption, dose reduction, or discontinuation; and assessing patient progress throughout the duration of the study. access to saquinavir will be determined by a lottery system; 60 percent of the program slots will be reserved for patients with cd4 counts of 50 or less and the remaining 40 percent of the slots will be devoted to patients with cd4 counts between 51 and 300.

Eligibility criteria:
inclusion criteria patients must have: * sero-positivity for hiv -1 antibody by an elisa test, with confirmation by an alternative method. * cd4 count \<= 300 cells/mm3 (within 4 weeks prior to entry). * signed, informed consent from a parent or legal guardian for patients \< 18 years of age. * failed previous therapy with or be intolerant to other registered anti-retroviral drugs. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * eligibility for any controlled clinical study of any experimental hiv therapy. * grade 4 hematologic and/or grade 3 hematologic toxicity at baseline. patients with the following prior conditions are excluded: known hypersensitivity to saquinavir or other protease inhibitors. 1. drugs, such as rifampin and rifabutin, which induce hepatic enzymes are likely to result in decreased levels of saquinavir and, therefore, should be avoided where possible. * concomitant therapy and treatment should be kept at a minimum. * current participation in any study formally excluding concomitant treatment with experimental drugs. 1. saquinavir can be used in combination with other registered anti-retroviral drugs such as zdv, ddc and/or ddl. other not yet registered anti-retroviral drugs can be used in combination with saquinavir when these drugs are widely available in the respective country or when they are allowed in combination treatment in any on-going clinical study. * prophylactic treatment for any opportunistic infections.

Keywords: zalcitabine didanosine drug therapy, combination zidovudine hiv protease inhibitors saquinavir patient selection anti-hiv agents
hypoallergenic infant formula containing starch and the probiotic: effect on gastric emptying

Conditions: Regurgitation, Gastric

Summary: the primary objective of this trial is to show that an hypoallergenic infant starter formula containing starch and the probiotic l. reuteri decreases the severity of regurgitation/spitting-up in infants presenting regurgitation/spitting-up , and who have taken it for 4 weeks, in comparison with a standard infant starter formula.

the primary objective of this trial is to show that the test formula (ha formula + starch + l. reuteri) decreases the severity (frequency + volume) of regurgitation/spitting-up in infants and ultrasound gastric emptying time, compared to a classical infant starter formula.

Eligibility criteria:
inclusion criteria: * full term infant (37 weeks ≤ gestation ≤ 42 weeks) * age of infant between 5 days and 5 months * nga * infant exclusively formula-fed at enrollment * presenting regurgitation/spitting-up according to the parents' perception * vandenplas score of at least 2 and maximum 5 * having obtained the subject's legal representative's written informed consent exclusion criteria: * previous antireflux treatment * previous consumption of ar infant formula or external thickener * previous consumption of a formula with l. reuteri * cow's milk allergy symptoms according to medical decision * congenital illness or malformation that may affect growth * significant pre-natal and/or post-natal disease * newborn whose parents / caregivers cannot be expected to comply with study procedures * newborn currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
differential immune effects of natalizumab

Conditions: Multiple Sclerosis, Relapsing Remitting

Summary: natalizumab is a humanized monoclonal antibody directed against very late activation antigene 4 (vla-4) and has a potent effect on disease activity in multiple sclerosis (ms). a blockade of vla-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (cns) immune surveillance.

longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural cd4+cd25+ regulatory t cells (tregs).

Eligibility criteria:
inclusion criteria: * relapsing remitting ms * indication for natalizumab treatment exclusion criteria: * other disease modifying agents within 2 weeks

Keywords: natalizumab multiple sclerosis
intravitreal faricimab injections or fluocinolone acetonide (0.19 mg) intravitreal implants vs observation for prevention of va loss due to radiation retinopathy

Conditions: Radiation Retinopathy; Visual Impairment

Summary: this randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (fac) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

the primary objectives are to compare long-term visual acuity outcomes in eyes that receive repeated treatment with faricimab or fluocinolone acetonide intravitreal implants with those observed initially and treated only if macular edema (me) develops. the secondary objectives are to determine if repeated treatment with faricimab or fluocinolone acetonide intravitreal implants versus observation can prevent or alter the course of me from radiation retinopathy and to evaluate the natural history of radiation retinopathy with multimodal imaging including widefield color photographs, widefield fluorescein angiography and octa.

Eligibility criteria:
key inclusion criteria * primary uveal melanoma (excluding iris melanoma) receiving primary treatment with plaque brachytherapy * absence of unrelated cause of visual loss * baseline visual acuity ≥ 34 letters (20/200 snellen equivalent or better) * posterior tumor margin \>0 mm from the center of the macula (i.e., tumor is not under the geometric center of the fovea) * posterior tumor margin \>0 mm from the closest disc margin (i.e., tumor is not touching the edge of the optic disc) * calculated total dose to center of the macula ≥30 gy key exclusion criteria * opaque media * inability to undergo fluorescein angiography * less than 18 years of age * prior vitrectomy * intraocular pressure (iop) ≥ 25 mmhg or history of steroid- induced iop elevation that required treatment at baseline * iop ≥ 25 mmhg at randomization or increase in iop ≥ 8 mmhg from baseline to randomization (following steroid challenge

Keywords: visual acuity radiation retinopathy faricima fluocinolone acetonide
early infectious disease consultations in staphylococcus aureus bacteremia

Conditions: Staphylococcus Aureus Bacteremia

Summary: the primary objective is to determine if early infectious disease (id) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from staphylococcus aureus bacteremia (sab). this study will also determine if such consultations could reduce the duration of hospitalisation, recurrence and financial costs in patients with this infection.

bacteremia is a serious manifestation of staphylococcus aureus infection with an attributable mortality as high as 25% in mrsa bacteremia. more than a third of patients end up with complications such as endocarditis, osteomyelitis or pneumonia. overall the outcome of patients with respect to mortality or recurrence is better in patients who have an eradicable focus and have received an appropriate antibiotic dose and duration. also complicated bacteremia is more common in patients with * persistent bacteremia or fever * prosthetic device * new murmur * skin findings of a systemic infection based on this evidence, an id consultation could improve the outcomes of patients with sab by * advising adequate antibiotic dosage and duration * sourcing out and counselling eradication of any focus of infection

Eligibility criteria:
inclusion criteria: * all inpatients at the national university hospital with staphylococcus aureus (both methicillin sensitive and methicillin resistant) bacteremia isolated within the defined time period exclusion criteria: * patients who died or were discharged before the notification from the laboratory * neonates * polymicrobial bacteremia

Keywords: staphylococcus aureus bacteremia outcome mortality recurrence infectious diseases specialists
hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels: a cohort study.

Conditions: Hemorrhage

Summary: assessment of pulp inflammation by hemostasis achievement after pulp exposure

the possibility has been raised of diagnosing pulpal pathological status using the cytokines that are released during the inflammation process in healthy as well as infected tooth pulp. cytokines are small polypeptides secreted by leucocytes and other inflammatory cells and are known to play important roles in the intensity and duration of the immune response

Eligibility criteria:
inclusion criteria: 1. healthy children 2. patients had not used any inflammatory medications 3. primary molar teeth of these children were included based on the following clinical and radiographic criteria: 1. no clinical symptoms or evidence of pulp degeneration (pain on percussion, history of swelling or sinus tract 2. no spontaneous pain 3. no radiographic signs of internal or external resorption, widened periodontal ligament space, or furcal/periapical radiolucency 4. physiological root resorption of no more than one third the root length 5. a deep caries lesion with a likelihood of pulp exposure during caries removal exclusion criteria: * patients used any anti-inflammatory medication
comparison of deep serratus anterior plane block and superficial serratus anterior plane block

Conditions: Pain, Postoperative; Serratus Anterior Plane Block; Thoracic Surgery, Video-Assisted

Summary: video-assisted thoracic surgery (vats) has become a common procedure in thoracic surgery. severe postoperative pain may be encountered in patients undergoing vats. analgesic methods such as thoracic paravertebral block (tpvb), intercostal block, serratus anterior plane block (sapb) and erector spina plane block (espb) are widely used for vats. among these methods, ultrasound (us) guided tpvb is the most preferred method. in recent years, the frequency of application of plane blocks as a component of multimodal analgesia has been increased. espb and sapb are some of them. there are two techniques for sapb application. in deep sapb (dsapb) application, local anesthetic agent is given under the serratus anterior muscle. in the superficial sapb (ssapb) application, the local anesthetic agent is given above the serratus anterior muscle. the mechanisms of regional analgesia techniques used after thoracic surgery operations are also different from each other. therefore, in this study, the analgesic efficacy of two different methods, dsapb and ssapb, will be compared.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * american society of anesthesiologists physical status i-ii-iii * body mass index between 18-30 kg/m2 * patients undergoing elective video assiste thoracoscopic surgery exclusion criteria: * patient refusing the procedure * history of chronic analgesic therapy * history of local anesthetic allergy * infection in the intervention area * patients with bleeding disorders * emergency surgery

Keywords: postoperative pain serratus anterior plane block video-assisted thoracic surgery vats
ct-2103 in treating patients with recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer

Conditions: Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma

Summary: phase ii trial to study the effectiveness of ct-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

primary objectives: i. determine the antitumor activity of polyglutamate paclitaxel (ct-2103) as third-line treatment for patients with recurrent or persistent ovarian epithelial or primary peritoneal cancer. ii. determine the nature and degree of toxicity of this drug in these patients. outline: this is a multicenter study. patients receive polyglutamate paclitaxel (ct-2103) iv over 10-20 minutes on day 1. courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * histologically confirmed recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer after second-line therapy * received 1 prior platinum-based first-line chemotherapy regimen and 1 prior second-line (non-platinum, non-taxane) chemotherapy regimen * at least 1 unidimensionally measurable lesion * at least 20 mm by conventional techniques or at least 10 mm by spiral ct scan * at least 1 target lesion that has not previously been irradiated * ineligible for a higher priority gog protocol (if one exists) * ineligible for the currently active phase ii cytotoxic protocol for platinum-resistant disease * performance status - gog 0-2 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * no active bleeding * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot no greater than 2.5 times uln * alkaline phosphatase no greater than 2.5 times uln * pt or ptt less than uln * creatinine no greater than 1.5 times uln * no uncontrolled hypertension * no uncompensated congestive heart failure * no symptomatic coronary artery disease * no myocardial infarction within the past 6 months * no sensory or motor neuropathy greater than grade 1 * no active infection requiring antibiotics * no other invasive malignancy within the past 5 years except nonmelanoma skin cancer * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * at least 3 weeks since prior biological therapy or immunotherapy directed at the malignancy * no prior polyglutamate paclitaxel (ct-2103) * recovered from prior chemotherapy * at least 1 week since prior hormonal therapy directed at the malignancy * concurrent hormone replacement therapy allowed * recovered from prior radiotherapy * no prior radiotherapy to more than 25% of bone marrow * recovered from prior surgery * at least 3 weeks since other prior therapy directed at the malignancy * no prior therapy for another malignancy that would preclude this study * no concurrent amifostine or other protective reagents
natural history of eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: researchers are trying to understand the course of eosinophilic esophagitis (eoe), its progression and effects of treatments.

investigators will identify patients from their database who have been diagnosed with eosinophilic esophagitis (ee) from the study period 2000 to 2008, based on clinical features and biopsy findings. participants will be offered a follow up evaluation that includes: evaluation by the principal investigator, completion of questionnaires, esophagram and esophageal sponge (esophacap) cytology.

Eligibility criteria:
inclusion criteria: * adults 18 years of age and older * previous participation in the natural history followup study exclusion criteria: * inability to read due to: blindness, cognitive dysfunction, or english language illiteracy * pregnant women
workplace intervention: activity monitoring as a tool for corporate wellness and weight loss

Conditions: Obesity

Summary: is a one-year intervention with treadmill desks associated with increased employee daily physical activity and decreased sedentariness. 36 employees with sedentary jobs (87 + 27 kg, bmi 29 + 7 kg/m2) used a treadmill desk for one year. daily physical activity, work performance, body composition, and blood variables were measured at baseline and 6 and 12 months after the treadmill desk intervention.


Eligibility criteria:
inclusion criteria: * subjects will be recruited regardless of race/ethnicity. exclusion criteria: * definite termination criteria. * request by subject to leave study. * evidence of deliberate non-compliance (e.g.; placing activity instruments on another individual, deliberate destruction of instruments). * pregnancy. * alcohol abuse; elicit drug abuse. * development of chronic condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., grave's disease, hypothyroidism, rheumatoid arthritis requiring steroids or limiting mobility, congestive cardiac failure, neurological disorder such as multiple sclerosis or stroke). * development of acute condition that is likely to impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate (e.g., motor vehicle accident with multiple fractures, myocardial infarction, major depression). potential termination criteria. development of acute or chronic condition that may impact on metabolic variables or requiring medications likely to impact on metabolic variables or likely to result in subject being unable to participate. subjects will be reviewed on a subject-by-subject basis and will be reported to the safety-monitoring panel. specific action plans are pre-assigned for: * diabetes (two fasting plasma glucose values \>126 mg/dl). here, glycosylated hemoglobin will be measured three monthly (by the study) and subjects referred to their local physician for preventative screening. subjects will be excluded from further study with any glycosylated hemoglobin value of \>8% or symptomatic hyperglycemia. * depression or low mood. here, all patients will be asked to be evaluated by their primary care physician and if appropriate referred to a psychiatrist. the opinion of the psychiatrist will be used to determine continuance or termination in the protocol. this does not represent a comprehensive listing of criteria or causes. all subjects who withdraw or whom are withdrawn from the study or whom are considering/being considered for withdrawal will be referred to the safety-monitoring panel. these subjects' data will be scrutinized (whether terminated or not) separately to assess for association of intervention with a specific adverse outcome.